Online citations, reference lists, and bibliographies.
← Back to Search

5-hydroxytryptamine-3 Receptor Antagonist With Or Without Short-course Dexamethasone In The Prophylaxis Of Radiation Induced Emesis: A Placebo-controlled Randomized Trial Of The National Cancer Institute Of Canada Clinical Trials Group (SC19).

R. Wong, N. Paul, K. Ding, M. Whitehead, Michael Brundage, A. Fyles, D. Wilke, A. Nabid, A. Fortin, D. Wilson, M. McKenzie, I. Ackerman, L. Souhami, P. Chabot, J. Pater
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To evaluate the effectiveness of prophylactic dexamethasone for the control of radiation induced emesis (RIE) when added to ondansetron during days 1 to 5 of fractionated radiotherapy. The study had two hypotheses: ondansetron and dexamethasone could provide superior control of RIE over ondansetron alone during the prophylactic period and; the combination could provide sustained control of RIE during subsequent fractions of radiotherapy. PATIENTS AND METHODS Between May 2001 to Jan 2004, 211 patients receiving radiotherapy (> or = 15 fractions) to the upper abdomen were randomly assigned to receive ondansetron 8 mg bid with either dexamethasone 4 mg daily or placebo during fractions 1 to 5. Rescue antiemetics were provided. RESULTS During the prophylactic period there was a trend for improved complete control of nausea in the dexamethasone arm (50% v 38%; P = .06) while complete and partial control of emesis, average nausea score, and use of rescue medications were similar in the two groups. During the overall study period patients receiving dexamethasone had better complete control of emesis (23% v 12%; P = .02) and a lower average nausea score (0.28 v 0.39; P = .03); there was a trend towards less use of rescue medications with dexamethasone (70% v 80%; P = .09); other outcomes were similar on the two arms. Quality of life analysis showed a significant difference in appetite. CONCLUSION The addition of dexamethasone to ondansetron as prophylaxis provides a modest improvement in protection against RIE during moderately emetogenic fractionated radiotherapy. It is a potentially useful addition to 5-hydroxytryptamine-3 receptor antagonists in this setting.
This paper references
10.1097/01.MLR.0000062554.74615.4C
Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation
G. Norman (2003)
10.1007/BF01788845
A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients
P. Bey (2005)
10.1016/S0936-6555(05)80086-X
A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy.
T. Priestman (1993)
10.1016/S0936-6555(05)80790-3
Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
T. Priestman (1990)
10.1007/s005200050119
Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy
A. Sykes (1997)
10.1093/OXFORDJOURNALS.ANNONC.A010675
A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy.
L. Franzén (1996)
10.1200/JCO.1994.12.11.2432
Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation.
T. Spitzer (1994)
10.1200/JCO.1999.17.9.2971
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.
R. Gralla (1999)
10.1007/978-3-642-70479-6_8
Mechanisms and Treatment of Radiation-Induced Nausea and Vomiting
R. Young (1986)
10.1097/00005650-200110000-00002
Relation of Distribution- and Anchor-Based Approaches in Interpretation of Changes in Health-Related Quality of Life
G. Norman (2001)
10.1016/S1388-9842(03)00101-6
Selection of endpoints for heart failure clinical trials
L. Zanolla (2003)
10.1093/ajhp/56.8.729
ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery.
M. Andria (1999)
10.1200/JCO.2000.18.9.1960
Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study.
P. Kirkbride (2000)
10.1016/S0959-8049(98)00161-0
Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review.
M. Tramèr (1998)
10.1016/J.EJCA.2004.10.017
Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group.
D. Osoba (2005)
10.1007/s00520-004-0705-3
Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines
P. Feyer (2004)
NCCN antiemesis practice guidelines.
D. Ettinger (1997)
10.1016/0305-7372(91)90009-O
The current role of anti-emetic drugs in oncology: a recent revolution in patient symptom control.
S. Sagar (1991)
10.1016/S0936-6555(97)80011-8
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study.
V. Khoo (1997)
10.1093/HUMREP/DEH322
Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?
R. Legro (2004)
Measurement of end points in heart failure trials: jousting at windmills?
P. Hauptman (2004)
10.1097/00043426-200210000-00004
Assessing the overall impact of therapy: it's not so simple.
P. Breitfeld (2002)
10.1053/CLON.1999.9077
Efficacy of an Ondansetron Orally Disintegrating Tablet: A Novel Oral Formulation of this 5-HT3 Receptor Antagonist in the Treatment of Fractionated Radiotherapy-Induced Nausea and Emesis
J. Lebourgeois (1999)
Granisetron in the prevention of irradiation-induced emesis.
H. Prentice (1995)
10.1046/j.1525-1497.2003.20203.x
Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease
K. Wyrwich (2007)
10.1016/J.JCLINEPI.2003.07.009
Evaluation of the results of a randomized controlled trial: how to define changes between baseline and follow-up.
J. Twisk (2004)
10.1016/S0009-9260(79)80203-2
The acute radiation syndrome. A memorial to William Michael Court-Brown.
C. Danjoux (1979)
10.1136/bmj.1.4814.802
Symptomatic Disturbance after Single Therapeutic Dose of X Rays
W. Brown (1953)



This paper is referenced by
10.6004/jnccn.2004.0037
Antiemesis clinical practice guidelines in oncology.
D. Ettinger (2004)
10.3978/j.issn.2224-5820.2015.08.01
Latest advances in the management of radiation-induced pain flare, nausea and vomiting.
Nicholas Chiu (2016)
10.1016/B978-0-323-47674-4.00039-6
Nausea and Vomiting
John D. Hainsworth (2020)
10.1016/j.ejon.2009.10.005
Emesis and gastrointestinal problems during radiotherapy: a comparison of performance of daily activities between patients experiencing nausea and patients free from nausea.
A. Enblom (2010)
10.1007/s00520-008-0445-x
One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient
A. Enblom (2008)
10.1016/B978-1-4160-3431-5.00031-5
Symptom Management in Children with Cancer
C. Ullrich (2009)
10.1016/B978-1-4557-2865-7.00042-4
42 – Nausea and Vomiting
J. Hainsworth (2014)
10.1016/j.ijrobp.2009.05.071
Radiation dose-volume effects in the stomach and small bowel.
B. Kavanagh (2010)
10.1016/S1040-1741(08)70280-X
5-Hydroxytryptamine-3 Receptor Antagonist With or Without Short-Course Dexamethasone in the Prophylaxis of Radiation Induced Emesis: A Placebo-Controlled Randomized Trial of the National Cancer Institute of Canada Clinical Trials Group (SC19)
P. Loehrer (2007)
10.1016/j.ejphar.2013.09.069
Radiation induced nausea and vomiting.
P. Feyer (2014)
10.1200/JCO.2013.54.8149
Developing a service model that integrates palliative care throughout cancer care: the time is now.
A. Partridge (2014)
10.1007/s00520-016-3407-8
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting
C. Ruhlmann (2016)
AntiemesisPractice Guidelines in Oncology TM
D. Ettinger (2009)
NCCN Antiemesis Panel Members
S. Kirkegaard (2010)
10.1007/s13566-012-0030-2
Timing and duration of 5-HT3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: a systematic review of randomized and non-randomized studies
K. Dennis (2012)
10.1007/s00520-016-3540-4
Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT)
S. Ades (2016)
10.1097/SPC.0000000000000130
Nausea and vomiting induced by gastrointestinal radiation therapy: current status and future directions
K. Dennis (2015)
10.1007/978-1-907673-58-0_7
Antiemetic Prophylaxis of Radiotherapy-Induced Nausea and Vomiting
M. Aapro (2013)
10.3747/co.22.2395
Ondansetron rapidly dissolving film for the prophylactic treatment of radiation-induced nausea and vomiting-a pilot study.
E. Wong (2015)
10.1007/978-3-319-52619-5_107-1
Radiation Induced Nausea and Emesis (RINV)
K. Jordan (2019)
10.3747/co.21.2051
Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot study.
K. Dennis (2014)
Managing the adverse effects of radiation therapy.
Franklin J Berkey (2010)
10.1007/s00520-019-04870-6
Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic
Erin McKenzie (2019)
10.1007/s00520-013-2104-0
A prospective study of gastrointestinal radiation therapy-induced nausea and vomiting
Michael Poon (2013)
10.1155/2015/893013
Prophylactic Management of Radiation-Induced Nausea and Vomiting
P. Feyer (2015)
10.1201/9781315160627-23
Position of Appetite and Nausea in Symptom Clusters in Palliative Radiation Therapy
Selina Chow (2019)
10.1007/s00520-015-2617-9
Symptom clusters of gastrointestinal cancer patients undergoing radiotherapy using the Functional Living Index—Emesis (FLIE) quality-of-life tool
Michael Poon (2015)
10.1016/J.JMIR.2016.06.006
An Overview of Radiation-Induced Nausea and Vomiting.
L. Rowbottom (2016)
10.14694/EdBook_AM.2012.32.532
Antiemetic Use in Oncology: Updated Guideline Recommendations from ASCO.
E. Basch (2012)
10.1634/theoncologist.2017-0225
Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial.
Hiroaki Tsukuura (2018)
10.1038/bmt.2008.257
Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens
M. E. Trigg (2008)
10.1016/j.ijrobp.2010.08.060
Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials.
N. Salvo (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar